Testis Development Related Protein Antibodies

Patent metadata

Field	Value
Publication number	US-2026042829-A1
Application number	US-202519357836-A
Country	US
Kind code	A1
Filing date	Oct 14, 2025
Priority date	Apr 3, 2019
Publication date	Feb 12, 2026
Grant date	—

Abstract

This invention relates to the finding that testis development related protein (TDRP; also termed Immuno-moodulin or Imood herein) is a circulatory anxiogenic factor that modulates anxiety-like behaviour in mammalian models through the regulation of the immune system. Methods of treatment of mental disorders, such as anxiety, and TDRP antagonists for use in such methods are provided. Methods of diagnosing or monitoring a mental disorder in an individual by determining levels of TDRP in a sample and methods of screening for compounds that reduce levels of TDRP are provided.

First claim

1 . A method of treating mental disorder comprising administering a testis development related protein (TDRP) antagonist to an individual in need thereof.

2 . A method according to claim 1 wherein the mental disorder is characterised by anxiety-related behaviour.

3 . A method according to claim 1 or claim 2 wherein the mental disorder is an anxiety disorder.

4 . A method according to any one of claims 1 to 3 wherein the mental disorder is obsessive compulsive disorder (OCD).

5 . A method according to any one of the preceding claims wherein the individual has an immune condition.

6 . A method according to claim 5 wherein the individual is undergoing treatment for an immune condition.

7 . A method according to claim 5 or claim 6 wherein the immune condition is an autoimmune disorder.

8 . A method according to any one of claims 5 to 7 wherein the individual is undergoing treatment with an immunosuppressant.

9 . A method according to any one of the preceding claims wherein the TDRP antagonist reduces the expression, level, amount or concentration of TDRP in the circulatory system of the individual.

10 . A method according to any one of the preceding claims wherein the TDRP antagonist is an antibody molecule that specifically binds TDRP.

11 . A method according to any one of the preceding claims wherein the antibody molecule is 1B10 or 1C4

12 . An antibody molecule that specifically binds to TDRP, said antibody molecule comprising an antigen binding site that comprises a VH domain and a VL domain, wherein the VH domain comprises a VHCDR1 of SEQ ID NO: 3 or a variant thereof, a VHCDR2 of SEQ ID NO: 4 or a variant thereof, and a VHCDR3 of SEQ ID NO: 5 or a variant thereof.

13 . An antibody according to claim 12 wherein;
the VL domain comprises a VLCDR1 of SEQ ID NO: 6 or a variant thereof, a VLCDR2 of SEQ ID NO: 8 or a variant thereof, and a VLCDR3 of SEQ ID NO: 10 or a variant thereof; or
the VL domain comprises a VLCDR1 of SEQ ID NO: 7 or a variant thereof, a VLCDR2 of SEQ ID NO: 9 or a variant thereof, and a VLCDR3 of SEQ ID NO: 10 or a variant thereof

14 . An antibody molecule according to claim 12 or claim 13 wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 11 or a variant thereof.

15 . An antibody molecule according to any one of claims 12 to 14 wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14 or a variant thereof.

16 . An antibody molecule that specifically binds to TDRP, said antibody molecule comprising an antigen binding site that comprises a VH domain and a VL domain, wherein the VH domain comprises a VHCDR1 of SEQ ID NO: 18 or a variant thereof, a VHCDR2 of SEQ ID NO: 19 or a variant thereof, and a VHCDR3 of SEQ ID NO: 20 or a variant thereof; and the VL domain comprises a VLCDR1 of SEQ ID NO: 21 or a variant thereof, a VLCDR2 of SEQ ID NO: 22 or a variant thereof, and a VLCDR3 of SEQ ID NO: 23 or a variant thereof.

17 . An antibody molecule according to claim 16 wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 24 or a variant thereof.

18 . An antibody molecule according to claim 16 or claim 17 wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 26 or a variant thereof.

19 . A method according to any one of claims 1 to 11 wherein the TDRP antagonist is an antibody molecule according to any one of claims 12 to 18 .

20 . A TDRP antagonist for use in a method of treatment of a mental disorder

21 . A TDRP antagonist for use according to claim 20 , wherein the method is a method according to any one of claims 1 to 11 .

22 . A TDRP antagonist for use according to claim 20 or claim 21 wherein the TDRP antagonist is an antibody molecule according to any one of claims 12 to 18 .

23 . Use of a TDRP antagonist in the manufacture of a medicament for use in a method of treatment of a mental disorder.

24 . Use according to claim 23 wherein the method is a method according to any one of claims 1 to 11 .

25 . Use according to claim 23 or claim 24 wherein the TDRP antagonist is an antibody molecule according to any one of claims 12 to 18 .

26 . A pharmaceutical composition comprising a therapeutically effective amount of TDRP antagonist and a pharmaceutically acceptable excipient.

27 . A pharmaceutical composition according to claim 26 wherein the TDRP antagonist is an antibody molecule according to any one of claims 12 to 18 .

28 . A pharmaceutical composition according to claim 26 or claim 27 for use in a method according to any one of claims 1 to 11 .

29 . A method of diagnosing a mental disorder in an individual; identifying an individual at increased risk of suffering from a mental disorder, or determining the anxiety of an individual, the method comprising;
determining the expression, level, amount or concentration of TDRP in a sample obtained from an individual.

30 . A method of monitoring an individual undergoing treatment comprising;
determining the expression, level, amount or concentration of TDRP in a sample obtained from an individual undergoing treatment.

31 . A method according to claim 30 wherein the individual is undergoing treatment for an immune condition.

32 . A method according to claim 30 wherein the individual is undergoing treatment for a mental disorder

33 . A method according to any one of claims 30 to 32 wherein the sample is a blood, serum or plasma sample.

34 . A method according to any one of claims 30 to 33 wherein the sample comprises PBMCs.

35 . A method according to claim 34 wherein the method comprises determining the expression of TDRP in a sample of PBMCs obtained from the individual.

36 . A method of screening for a compound with therapeutic activity against a mental disorder comprising;
determining the binding of a test compound to isolated TDRP, binding to TDRP being indicative that the compound has therapeutic activity against a mental disorder.

37 . A method of screening for a compound with therapeutic activity against a mental disorder comprising;
determining the effect of a test compound on the expression, level, amount or concentration of TDRP in a non-human mammal, a decrease in expression, level, amount or concentration of TDRP being indicative that the compound has therapeutic activity against a mental disorder.

38 . A method according to claim 36 or 37 wherein the activity is anxiolytic activity.

39 . A method according to any one of claims 36 to 38 further comprising determining the effect of the text compound on anxiety-related behaviour in a non-human mammal.

40 . A method of determining the activation of T cells in an individual comprising;
determining the expression of TDRP in a sample of T cells obtained from the individual.

Assignees

• Univ London Queen Mary

Inventors

• D'Acquisto Fulvio

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A01K2267/0356

  Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy · CPC title